Literature DB >> 14592816

Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations.

David P Steensma1, Douglas R Higgs, Chris A Fisher, Richard J Gibbons.   

Abstract

Acquired somatic mutations in ATRX, an X-linked gene encoding a chromatin-associated protein, were recently identified in 4 patients with the rare subtype of myelodysplastic syndrome (MDS) associated with thalassemia (ATMDS). Here we describe a series of novel point mutations in ATRX detected in archival DNA samples from marrow and/or blood of patients with ATMDS by use of denaturing high-performance liquid chromatography (DHPLC), a technique sensitive to low-level mosaicism. Two of the new mutations result in changes in amino acids altered in previously described pedigrees with germ line ATRX mutations (ATR-X syndrome), but the hematologic abnormalities were much more severe in the patients with ATMDS than in the corresponding constitutional cases. In one ATMDS case where DNA samples from several time points were available, the proportion of ATRX-mutant subclones correlated with changes in the amount of hemoglobin H. This study strengthens the link between acquired, somatic ATRX mutations and ATMDS, illustrates how molecular defects associated with MDS and other hematologic malignancies masked by somatic mosaicism may be detected by DHPLC, and shows that additional factors increase the severity of the hematologic phenotype of ATRX mutations in ATMDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592816     DOI: 10.1182/blood-2003-09-3360

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

2.  [Myelodysplastic syndromes].

Authors:  A Giagounidis
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

Review 3.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

Review 4.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

5.  α-Thalassemia, mental retardation, and myelodysplastic syndrome.

Authors:  Richard J Gibbons
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 6.  Centromere studies in the era of 'telomere-to-telomere' genomics.

Authors:  Karen H Miga
Journal:  Exp Cell Res       Date:  2020-06-03       Impact factor: 3.905

7.  Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.

Authors:  John D Phillips; David P Steensma; Michael A Pulsipher; Gerald J Spangrude; James P Kushner
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

Review 8.  Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease.

Authors:  Rabindranath De La Fuente; Claudia Baumann; Maria M Viveiros
Journal:  Reproduction       Date:  2011-06-08       Impact factor: 3.906

Review 9.  ATRX: the case of a peculiar chromatin remodeler.

Authors:  Kajan Ratnakumar; Emily Bernstein
Journal:  Epigenetics       Date:  2012-12-18       Impact factor: 4.528

10.  Compromised genomic integrity impedes muscle growth after Atrx inactivation.

Authors:  Michael S Huh; Tina Price O'Dea; Dahmane Ouazia; Bruce C McKay; Gianni Parise; Robin J Parks; Michael A Rudnicki; David J Picketts
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.